Hydroxyurea for Children with Sickle Cell Disease

被引:57
作者
Heeney, Matthew M. [1 ,2 ]
Ware, Russell E. [3 ]
机构
[1] Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
[3] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA
关键词
Sickle cell anemia; Antisickling agents; Hydroxyurea; Child; Human; FETAL-HEMOGLOBIN PRODUCTION; RECURRENT STROKE; F PRODUCTION; ANEMIA; THERAPY; INDUCTION; SEVERITY; ADULT; PREVENTION; 5-AZACYTIDINE;
D O I
10.1016/j.hoc.2009.11.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage. There are limited data regarding hydroxyurea's ability to prevent or diminish organ dysfunction, and the long-term risks of hydroxyurea therapy remain incompletely defined. Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD.
引用
收藏
页码:199 / +
页数:17
相关论文
共 72 条
[1]  
Atweh GF, 1999, BLOOD, V93, P1790
[2]   THE PAINFUL CRISIS OF HOMOZYGOUS SICKLE-CELL DISEASE - A STUDY OF RISK-FACTORS [J].
BAUM, KF ;
DUNN, DT ;
MAUDE, GH ;
SERJEANT, GR .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (07) :1231-1234
[3]   SOCIOBEHAVIORAL DETERMINANTS OF COMPLIANCE WITH HEALTH AND MEDICAL CARE RECOMMENDATIONS [J].
BECKER, MH ;
MAIMAN, LA .
MEDICAL CARE, 1975, 13 (01) :10-24
[4]   A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy [J].
Bridges, KR ;
Barabino, GD ;
Brugnara, C ;
Cho, MR ;
Christoph, GW ;
Dover, G ;
Ewenstein, BM ;
Golan, DE ;
Guttmann, CRG ;
Hofrichter, J ;
Mulkern, RV ;
Zhang, B ;
Eaton, WA .
BLOOD, 1996, 88 (12) :4701-4710
[5]   Hydroxyurea in two pregnant women with sickle cell anemia [J].
Byrd, DC ;
Pitts, SR ;
Alexander, CK .
PHARMACOTHERAPY, 1999, 19 (12) :1459-1462
[6]  
CHARACHE S, 1992, BLOOD, V79, P2555
[7]   EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA [J].
CHARACHE, S ;
TERRIN, ML ;
MOORE, RD ;
DOVER, GJ ;
BARTON, FB ;
ECKERT, SV ;
MCMAHON, RP ;
BONDS, DR ;
ORRINGER, E ;
JONES, S ;
STRAYHORN, D ;
ROSSE, W ;
PHILLIPS, G ;
PEACE, D ;
JOHNSONTELFAIR, A ;
MILNER, P ;
KUTLAR, A ;
TRACY, A ;
BALLAS, SK ;
ALLEN, GE ;
MOSHANG, J ;
SCOTT, B ;
STEINBERG, M ;
ANDERSON, A ;
SABAHI, V ;
PEGELOW, C ;
TEMPLE, D ;
CASE, E ;
HARRELL, R ;
CHILDERIE, S ;
EMBURY, S ;
SCHMIDT, B ;
DAVIES, D ;
KOSHY, M ;
TALISCHYZAHED, N ;
DORN, L ;
PENDARVIS, G ;
MCGEE, M ;
TELFER, M ;
DAVIS, A ;
CASTRO, O ;
FINKE, H ;
PERLIN, E ;
SITEMAN, J ;
GASCON, P ;
DIPAOLO, P ;
GARGIULO, S ;
ECKMAN, J ;
BAILEY, JH ;
PLATT, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1317-1322
[8]  
Charache S, 1990, Adv Pediatr, V37, P1
[9]  
CHARACHE S, 1987, BLOOD, V69, P109
[10]   The role of hydroxyurea in the management of sickle cell disease [J].
Davies, SC ;
Gilmore, A .
BLOOD REVIEWS, 2003, 17 (02) :99-109